Approximately 65% of patients with diffuse large B-cell lymphoma are cured with first-line
therapy. However, approximately 10% to 15% exhibit primary refractory disease, and 20% to …

Primary mediastinal large B-cell lymphoma (PMBCL) is an aggressive B-cell lymphoma
arising from thymic B-cells having clinicopathologic features distinct from systemic diffuse …

Primary mediastinal (thymic) large B‐cell lymphoma (PMBCL) is an uncommon subtype of
non‐Hodgkin lymphoma (NHL) that presents with a mediastinal mass and has unique …

The management of diffuse large B-cell lymphoma (DLBCL) has been gradually evolving
since the discovery of its 2 major forms, the germinal center B-like (GCB) and activated B …

The management of primary mediastinal large B-cell lymphoma (PMBCL) requires a
balance between optimizing chances of cure and reducing risk of long-term toxicities. The …

Simple Summary Mass spectrometry-based proteomics studies have suggested various
proteins as diagnostic, prognostic, and druggable targets in diffuse large B cell lymphoma …

Background The upregulated expression of the JAK/STAT pathway promotes tumor growth
in Hodgkin lymphoma (HL) and primary mediastinal large B-cell lymphoma (PMBCL). Based …

This study describes short-term and long-term healthcare resource utilization (HRU) and
costs following an allogeneic hematopoietic stem cell transplant (HSCT) in adult patients …

OBJECTIVE. The purpose of this article is to provide a primer for radiologists focused on
integrating the radiologic, pathologic, and clinical features of primary mediastinal large B …

Purpose Outcomes in primary mediastinal B cell lymphoma (PMBL) improved with the
introduction of dose intense treatments, consolidation radiotherapy and rituximab. DA …